CRON vs NAGE
Cronos Group Inc. and Niagen Bioscience, Inc., side by side — 9 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CRON | NAGE |
|---|---|---|
| Revenue | $193.4M | $129.4M |
| Net income | $-9.4M | $17.4M |
| Gross margin | 42.8% | 64.3% |
| Net margin | −2.0% | 13.4% |
| Return on equity | −0.9% | 28.3% |
| Diluted EPS | −$0.02 | $0.20 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $149,000 | · |
| Equity | $1.1B | $76.5M |
| Net debt / equity | · | · |
| Current ratio | 19.59× | 4.86× |
| Revenue CAGR 5y | 28.9% | 16.9% |
| Profit CAGR 5y | · | · |
CRON bills 1.5× the revenue of NAGE, and CRON closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
9 years side by side
| Fiscal year | CRON | NAGE |
|---|---|---|
| FY2025 | $193.4M | $129.4M |
| FY2024 | $161.8M | $99.6M |
| FY2023 | $120.3M | $83.6M |
| FY2022 | $109.3M | $72.0M |
| FY2021 | $79.6M | $67.4M |
| FY2020 | $54.4M | $59.3M |
| FY2019 | $25.6M | $46.3M |
| FY2018 | $13.2M | $31.6M |
| FY2017 | $3.1M | $21.2M |
Bottom line
| Fiscal year | CRON | NAGE |
|---|---|---|
| FY2025 | $-9.4M | $17.4M |
| FY2024 | $41.1M | $8.6M |
| FY2023 | $-74.0M | $-4.9M |
| FY2022 | $-168.7M | $-16.5M |
| FY2021 | $-396.1M | $-27.1M |
| FY2020 | $-73.1M | $-19.9M |
| FY2019 | $1.2B | $-32.1M |
| FY2018 | $-21.6M | $-33.3M |
| FY2017 | $-1.5M | $-11.4M |
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$63,940,000 | CRON |
| FY2024 | +$62,224,000 | CRON |
| FY2023 | +$36,700,000 | CRON |
| FY2022 | +$37,251,000 | CRON |
| FY2021 | +$12,163,000 | CRON |
| FY2020 | −$4,904,000 | NAGE |
| FY2019 | −$20,652,000 | NAGE |
| FY2018 | −$18,323,000 | NAGE |
| FY2017 | −$18,054,000 | NAGE |
The higher-revenue side has changed between CRON and NAGE over this period. The gap has widened since the earliest year compared.
9 of 16 comparable fiscal years — a year missing data on either side is not counted.
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −15.4 pp | NAGE |
| FY2024 | +25.4 pp | CRON |
| FY2023 | −79.5 pp | NAGE |
| FY2022 | −171.6 pp | NAGE |
| FY2021 | −575.0 pp | NAGE |
| FY2020 | −127.5 pp | NAGE |
| FY2018 | −74.4 pp | NAGE |
| FY2017 | +6.5 pp | CRON |
The higher net margin has changed hands between CRON and NAGE over this period.
8 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CRON's net margin has been more volatile than NAGE's over the 8 comparable fiscal years — 190.3 percentage points of standard deviation against 36.0.
8 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between CRON and NAGE over these 8 fiscal years — CRON led in 2 and NAGE in 6.
8 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NAGE's return on equity has been more volatile than CRON's over the 9 comparable fiscal years — 55.9 percentage points of standard deviation against 42.4.
9 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CRON and NAGE over these 9 fiscal years — CRON led in 7 and NAGE in 2.
9 of 16 comparable fiscal years — a year missing data on either side is not counted.